相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis
Jun-Shuai Xue et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Improved AAV vector system for cell-type-specific RNA interference
Seung-Chan Kim et al.
JOURNAL OF NEUROSCIENCE METHODS (2022)
The role of indoleamine 2,3-dioxygenase in allergic disorders
Seyed-Alireza Esmaeili et al.
MOLECULAR BIOLOGY REPORTS (2022)
Adenovirus vaccine therapy with CD137L promotes CD8+DCs-mediated multifunctional CD8+T cell immunity and elicits potent anti-tumor activity
Jiage Ding et al.
PHARMACOLOGICAL RESEARCH (2022)
Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti-PD-L1 Therapy
Yucheng Xiang et al.
SMALL (2022)
Anti-4-1BB antibody-based combination therapy augments antitumor immunity by enhancing CD11c+CD8+ T cells in renal cell carcinoma
Seong-A Ju et al.
ONCOLOGY LETTERS (2022)
TGF-β Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma
Kasia Trebska-McGowan et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2022)
Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges
Alessandro Poggi et al.
MOLECULAR THERAPY-ONCOLYTICS (2022)
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma
Tan-Huy Chu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Therapeutic efficacy of dendritic cell vaccine combined with programmed death 1 inhibitor for hepatocellular carcinoma
Chiao-Fang Teng et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Programmed death ligand 1 (PD-L1) plays a vital part in DC tolerogenicity induced by IFN-γ
Urban Svajger et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment
Valeria Lucarini et al.
CANCERS (2021)
Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial
S. Miwa et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3-dioxygenase 1 with functional effects on T cell priming
Simone P. Sittig et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2021)
Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma
Astrid Tschan-Plessl et al.
CYTOTHERAPY (2021)
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Qingyi Wang et al.
FRONTIERS IN IMMUNOLOGY (2021)
HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine
Zhaojin Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Targeting Inflammasome Activation in COVID-19: Delivery of RNA Interference-Based Therapeutic Molecules
Lealem Gedefaw et al.
BIOMEDICINES (2021)
MSC-like cells increase ability of monocyte-derived dendritic cells to polarize IL-17-/IL-10-producing T cells via CTLA-4
Anett Mazlo et al.
ISCIENCE (2021)
Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade
Kun Tu et al.
ACS APPLIED MATERIALS & INTERFACES (2021)
Programmed cell death protein-1 (PD-1) protects liver damage by suppressing IFN-γ expression in T cells in infants and neonatal mice
Xuangjie Guo et al.
BMC PEDIATRICS (2021)
Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells
Murat Tekguc et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy
Mona Yazdani et al.
SCIENTIFIC REPORTS (2021)
Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications
Ahmed Salah et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
Muhammad Khan et al.
FRONTIERS IN IMMUNOLOGY (2021)
Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
Xi Chen et al.
ACTA PHARMACEUTICA SINICA B (2020)
Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine
Hadi Hassannia et al.
IMMUNOLOGY (2020)
Targeting the 4-1BB costimulatory molecule through single chain antibodies promotes the human T-cell response
Salman Bagheri et al.
CELLULAR & MOLECULAR BIOLOGY LETTERS (2020)
Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T
Ravi A. Madan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Florent Petitprez et al.
FRONTIERS IN IMMUNOLOGY (2020)
Cell and tissue engineering in lymph nodes for cancer immunotherapy
Alexander J. Najibi et al.
ADVANCED DRUG DELIVERY REVIEWS (2020)
IL-12 from endogenous cDC1, and not vaccine DC, is required for Th1 induction
DiyaaElDin Ashour et al.
JCI INSIGHT (2020)
Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection
Benedetta Peruzzi et al.
IMMUNOLOGY (2020)
Cancer Acidity and Hypertonicity Contribute to Dysfunction of Tumor-Associated Dendritic Cells: Potential Impact on Antigen Cross-Presentation Machinery
Sven Burgdorf et al.
CANCERS (2020)
IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives
Caterina Lapenta et al.
VACCINES (2020)
Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside
Muhammad Imran Sajid et al.
PHARMACEUTICALS (2020)
Unleashing the Therapeutic Potential of Dendritic and T Cell Therapies Using RNA Interference
Mouldy Sioud
RNA INTERFERENCE AND CRISPR TECHNOLOGIES: TECHNICAL ADVANCES AND NEW THERAPEUTIC OPPORTUNITIES (2020)
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
Christopher Montemagno et al.
ONCOIMMUNOLOGY (2020)
Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia
Daniel Christoph Amberger et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2020)
SOLUBLE PROGRAMMED DEATH-1 (SPD-1) AND PROGRAMMED DEATH LIGAND 1 (SPD-L1) AS POTENTIAL BIOMARKERS FOR THE DIAGNOSIS AND PROGNOSIS OF GLIOMA PATIENTS
Shujun Liu et al.
JOURNAL OF MEDICAL BIOCHEMISTRY (2020)
Enhancing chimeric antigen receptor T-cell immunotherapy against cancer using a nanoemulsion-based vaccine targeting cross-presenting dendritic cells
Jack D. Chan et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2020)
Interactions among myeloid regulatory cells in cancer
Viktor Umansky et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Genetics of antigen processing and presentation
Adrian Kelly et al.
IMMUNOGENETICS (2019)
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes
Moritz Rapp et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Dendritic Cell-Mediated Th2 Immunity and Immune Disorders
Sunil Kumar et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Silencing of PD-L2/B7-DC by Topical Application of Small Interfering RNA Inhibits Elicitation of Contact Hypersensitivity
Emi Furusawa et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Rethinking Thymic Tolerance: Lessons from Mice
Sarah Inglesfield et al.
TRENDS IN IMMUNOLOGY (2019)
Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway
Te-Fu Tsai et al.
BIOSCIENCE REPORTS (2019)
Fcγ receptors and toll-like receptor 9 synergize to drive immune complex-induced dendritic cell maturation
Nicole L. J. Nelson et al.
CELLULAR IMMUNOLOGY (2019)
TGF-β signaling controls Foxp3 methylation and T reg cell differentiation by modulating Uhrf1 activity
Xiang Sun et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Cancer-Derived VEGF-C Increases Chemokine Production in Lymphatic Endothelial Cells to Promote CXCR2-Dependent Cancer Invasion and MDSC Recruitment
Jing-Yi Chen et al.
CANCERS (2019)
CD137L-DCs, Potent Immune-Stimulators-History, Characteristics, and Perspectives
Qun Zeng et al.
FRONTIERS IN IMMUNOLOGY (2019)
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
Margaret L. Axelrod et al.
CLINICAL CANCER RESEARCH (2019)
Professional and 'Amateur' Antigen-Presenting Cells In Type 2 Immunity
Martijn J. Schuijs et al.
TRENDS IN IMMUNOLOGY (2019)
Phenotypic and functional profile of IFN-α-differentiated dendritic cells (IFN-DCs) from HIV-infected individuals
Bruna Tereso Santillo et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Dendritic cell subsets in T cell programming: location dictates function
S. C. Eisenbarth
NATURE REVIEWS IMMUNOLOGY (2019)
The proatherosclerotic function of indoleamine 2, 3-dioxygenase 1 in the developmental stage of atherosclerosis
Heng Liang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Dendritic cell subsets
Christophe Macri et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2018)
CCL3 augments tumor rejection and enhances CD8(+) T cell infiltration through NK and CD103(+) dendritic cell recruitment via IFN
Frederick Allen et al.
ONCOIMMUNOLOGY (2018)
A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment
Anje Cauwels et al.
ONCOIMMUNOLOGY (2018)
TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in Breast Cancer
Alvaro de Mingo Pulido et al.
CANCER CELL (2018)
IL-10 induces an immune repressor pathway in sepsis by promoting S100A9 nuclear localization and MDSC development
Isatou Bah et al.
CELLULAR IMMUNOLOGY (2018)
Myeloid cell heterogeneity in cancer: not a single cell alike
Mate Kiss et al.
CELLULAR IMMUNOLOGY (2018)
Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect
Chenlu Liu et al.
IMMUNOLOGY LETTERS (2018)
Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy
Tsukasa Seya et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2018)
Dendritic cells in the regulation of immunity and inflammation
Cheng Qian et al.
SEMINARS IN IMMUNOLOGY (2018)
Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia
Yingying Wang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Aurelie Durgeau et al.
FRONTIERS IN IMMUNOLOGY (2018)
Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors
Chang-Long Chen et al.
ONCOIMMUNOLOGY (2018)
Towards superior dendritic-cell vaccines for cancer therapy
Mansi Saxena et al.
NATURE BIOMEDICAL ENGINEERING (2018)
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Linking cellular stress responses to systemic homeostasis
Lorenzo Galluzzi et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
Mandy van Gulijk et al.
FRONTIERS IN IMMUNOLOGY (2018)
Extracellular vesicles from mature dendritic cells (DC) differentiate monocytes into immature DC
Stefan Schierer et al.
LIFE SCIENCE ALLIANCE (2018)
Efficacy of intracellular immune checkpoint-silenced DC vaccine
Danhong Wang et al.
JCI INSIGHT (2018)
Multiple effects of CD40-CD40L axis in immunity against infection and cancer
Anjuman Ara et al.
IMMUNOTARGETS AND THERAPY (2018)
Rejection versus escape: the tumor MHC dilemma
Federico Garrido et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
Naoki Horikawa et al.
CLINICAL CANCER RESEARCH (2017)
Ipilimumab: from preclinical development to future clinical perspectives in melanoma
Paul Letendre et al.
FUTURE ONCOLOGY (2017)
Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition
Meredis Favreau et al.
HAEMATOLOGICA (2017)
Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Maria Carmen Ochoa et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
Mapping the human DC lineage through the integration of high-dimensional techniques
Peter See et al.
SCIENCE (2017)
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
Abhishek D. Garg et al.
TRENDS IN IMMUNOLOGY (2017)
The novel immunomodulator IMMUNEPOTENT CRP combined with chemotherapy agent increased the rate of immunogenic cell death and prevented melanoma growth
Maria Del Carmen Rodriguez-Salazar et al.
ONCOLOGY LETTERS (2017)
Induction of RNAi Responses by Short Left-Handed Hairpin RNAi Triggers
Jonathan C. Hagopian et al.
NUCLEIC ACID THERAPEUTICS (2017)
Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition
Meredis Favreau et al.
HAEMATOLOGICA (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Indoleamine 2,3-Dioxygenase and Tolerance: Where Are We Now?
Andrew L. Mellor et al.
FRONTIERS IN IMMUNOLOGY (2017)
Generation and functional characterization of MDSC-like cells
Annkristin Heine et al.
ONCOIMMUNOLOGY (2017)
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Abhishek D. Garg et al.
ONCOIMMUNOLOGY (2017)
Co-delivery of the NKT agonist -galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses
Reem Ghinnagow et al.
ONCOIMMUNOLOGY (2017)
CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer
Fee Bengsch et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
Sebastien Anguille et al.
BLOOD (2017)
Hematologic neoplasms: Dendritic cells vaccines in motion
Domenico Galati et al.
CLINICAL IMMUNOLOGY (2017)
Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine
Cody S. Lee et al.
GENES & DISEASES (2017)
CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations
Supot Nimanong et al.
CANCER RESEARCH (2017)
PD-1 expression on dendritic cells suppresses CD8(+) T cell function and antitumor immunity
Tong Seng Lim et al.
ONCOIMMUNOLOGY (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Modulation of innate immunity in the tumor microenvironment
Elena Gonzalez-Gugel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells
Toshiko Kamata et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation
A. D. Garg et al.
CELL DEATH AND DIFFERENTIATION (2016)
Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy
Alessandra da Cunha et al.
IMMUNOLOGY LETTERS (2016)
c-Src Suppresses Dendritic Cell Antitumor Activity via T Cell Ig and Mucin Protein-3 Receptor
Ravindra Gujar et al.
JOURNAL OF IMMUNOLOGY (2016)
Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines
Jingwei Liu et al.
JOURNAL OF IMMUNOTHERAPY (2016)
Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib
Steffen Filskov Sorensen et al.
LUNG CANCER (2016)
Transcriptional and functional characterization of CD137L-dendritic cells identifies a novel dendritic cell phenotype
Zulkarnain Harfuddin et al.
SCIENTIFIC REPORTS (2016)
TiM-3 Regulates Distinct Functions in Macrophages
Ranferi Ocana-Guzman et al.
FRONTIERS IN IMMUNOLOGY (2016)
Efficient Nontoxic Delivery of PD-L1 and PD-L2 siRNA Into Dendritic Cell Vaccines Using the Cationic Lipid SAINT-18
Mieke W. H. Roeven et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
A. Ray et al.
LEUKEMIA (2015)
Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1
Luara Isabela dos Santos et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Silenced suppressor of cytokine signaling 1 (SOCS1) enhances the maturation and antifungal immunity of dendritic cells in response to Candida albicans in vitro
Dongmei Shi et al.
IMMUNOLOGIC RESEARCH (2015)
Autocrine activation of canonical BMP signaling regulates PD-L1 and PD-L2 expression in human dendritic cells
Victor G. Martinez et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells
J. J. Pen et al.
GENE THERAPY (2014)
Immunoregulation of Dendritic Cells by the Receptor T cell Ig and Mucin Protein-3 via Bruton's Tyrosine Kinase and c-Src
Neeraj Maurya et al.
JOURNAL OF IMMUNOLOGY (2014)
Differential Impact of CD27 and 4-1BB Costimulation on Effector and Memory CD8 T Cell Generation following Peptide Immunization
Jane E. Willoughby et al.
JOURNAL OF IMMUNOLOGY (2014)
Targeted siRNA Silencing of Indoleamine 2, 3-Dioxygenase in Antigen-presenting Cells Using Mannose- conjugated Liposomes: A Novel Strategy for Treatment of Melanoma
Di Chen et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro
Shuo Wang et al.
ONCOTARGETS AND THERAPY (2014)
Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation
Willemijn Hobo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
Jacalyn Rosenblatt et al.
CLINICAL CANCER RESEARCH (2013)
Silencing IDO in dendritic cells: A novel approach to enhance cancer immunotherapy in a murine breast cancer model
Xiufen Zheng et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go
Angela Vasaturo et al.
FRONTIERS IN IMMUNOLOGY (2013)
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H. Vonderheide et al.
ONCOIMMUNOLOGY (2013)
The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues
Jurjen Tel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs
Shuxia Song et al.
EUROPEAN JOURNAL OF CANCER (2012)
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
W. Joost Lesterhuis et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1
Mi-Young Song et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205
Ali Badiee et al.
VACCINE (2007)
Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation
Seiichi Kuwajima et al.
NATURE IMMUNOLOGY (2006)
CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system
RK Zhong et al.
CYTOTHERAPY (2006)
SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling
K Evel-Kabler et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity
MF Kalady et al.
JOURNAL OF SURGICAL RESEARCH (2004)
4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12
D Laderach et al.
CELLULAR IMMUNOLOGY (2003)
Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens
N Okada et al.
BRITISH JOURNAL OF CANCER (2001)
分享论文
